Arena (ARNA -0.7%) rewards the VP of its regulatory affairs, Craig Audet, for his role in the...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Arena (ARNA -0.7%) rewards the VP of its regulatory affairs, Craig Audet, for his role in the company receiving FDA approval for weight-loss drug Belviq by promoting him to Senior VP, Operations and Head of Global Regulatory Affairs. Audet's new role will also include investor relations and alliance management. (PR)